Mariana Camoez

Mariana Camoez

Auto-generated profile, based on publicly available information

Mariana Camoez

Department of Microbiology, Hospital Universitari de Bellvitge, Institut D'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain; Research Network for Infectious Diseases (CIBERINFEC), ISCIII, Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
MCM. Camoez
M. Camoez
Josep M SierraJosep M Sierra
Josep M Sierra
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
MFM. Ferrer-Navarro
M. Ferrer-Navarro
Jordi VilaJordi Vila
Jordi Vila
Ignasi RocaIgnasi Roca
Ignasi Roca

1 September 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SGSilvia Gómez-Zorrilla
Silvia Gómez-Zorrilla
MCMariana Camoez
Mariana Camoez
FTFe Tubau
Fe Tubau
RCRosario Cañizares
Rosario Cañizares
EPElisabet Periche
Elisabet Periche
CPCarmen Peña
Carmen Peña
The potential role of Pseudomonas aeruginosa (PA) intestinal colonization in the subsequent development of infections has not been thoroughly investigated. The aims of this study were to assess the role of PA intestinal colonization as a predictor of subsequent infections and to investigate the risk factors associated with the development of PA infection in patients in the intensive care unit (ICU). For this purpose, a prospective study was conducted that included (i) active surveillance of PA rectal colonization at ICU admission and weekly until ICU discharge, (ii) detection of PA clinical infections, and (iii) genotypic analysis by pulsed-field gel electrophoresis (PFGE). A total of 414 patients were included, of whom 179 (43%) were colonized with PA. Among the 77 patients who developed PA infection, 69 (90%) had prior PA colonization, and 60 (87%) of these showed genotyping concordance between rectal and clinical isolates. The probability of PA infection 14 days after ICU admission was 26% for carriers versus 5% for noncarriers ( P < 0.001). Cox regression analysis identified prior PA rectal colonization as the main predictor of PA infection (hazard ratio [HR], 15.23; 95% confidence interval [CI], 6.9 to 33.7; P < 0.001). Prior use of nonantipseudomonal penicillins was also identified as an independent variable associated with PA infection (HR, 2.15; 95% CI, 1.3 to 3.55; P < 0.003). Our study demonstrated that prior PA rectal colonization is a key factor for developing PA infection.

1 November 2013 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
OGOriol Gasch
Oriol Gasch
MCM. Camoez
M. Camoez
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
BPB. Padilla
B. Padilla
VPV. Pintado
V. Pintado
MPMiquel Pujol
Miquel Pujol

19 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CGCarlota Gudiol
Carlota Gudiol
JAJosefina Ayats
Josefina Ayats
MCMariana Camoez
Mariana Camoez
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
CGCarolina Garcia-Vidal
Carolina Garcia-Vidal
JCJordi Carratala
Jordi Carratala
We conducted a prospective study to assess the risk factors, molecular epidemiology and outcome of bloodstream infection (BSI) due to Enterococcus faecium in hospitalized cancer patients. Between 2006 and 2012, a significant increase in vancomycin-susceptible E. faecium BSI was observed among cancer patients. Comparison of 54 episodes of BSI due to E. faecium with 38 episodes of BSI due to E. faecalis showed that previous use of carbapenems was the only independent risk factor for E. faecium acquisition (OR 10.24; 95% CI, 1.35-77.66). All E. faecium isolates were susceptible to glycopeptides, whereas 97% showed high-level resistance to ampicillin and ciprofloxacin. All 30 isolates available for genotyping belonged to the hospital-associated E. faecium lineages 17, 18 and 78. After 2009, most of the isolates belonged to ST117 (lineage 78). Patients with E. faecium BSI were more likely to receive inadequate initial empirical antibiotic therapy than patients with E. faecalis BSI, and time to adequate empirical antibiotic therapy was also longer in the former group. No significant differences were found between the two groups regarding early and overall case-fatality rates. Independent risk factors for overall case-fatality were current corticosteroids (OR 4.18; 95% CI, 1.34-13.01) and intensive care unit admission (OR 9.97; 95% CI, 1.96-50.63). The emergence of E. faecium among cancer patients is a concern since there are limited treatment options and it may presage the emergence of vancomycin-resistant enterococci. A rationale approach that combines infection control with antimicrobial stewardship.

1 October 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SGSilvia Gómez-Zorrilla
Silvia Gómez-Zorrilla
MCMariana Camoez
Mariana Camoez
FTFe Tubau
Fe Tubau
EPElisabet Periche
Elisabet Periche
RCRosario Cañizares
Rosario Cañizares
CPCarmen Peña
Carmen Peña
The intestinal reservoir is central to the epidemiology of Pseudomonas aeruginosa , but the dynamics of intestinal colonization by different phenotypes have been poorly described. To determine the impact of antimicrobial exposure on intestinal colonization by multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa , we screened intensive care unit (ICU) patients for rectal colonization on admission and at weekly intervals. During an 18-month study period, 414 ICU patients were enrolled, of whom 179 (43%) were colonized; 112 (63%) of these were identified at ICU admission and 67 (37%) during their ICU stay. At 10 days after ICU admission, the probabilities of carriage were 44%, 24%, and 24% for non-MDR, MDR-non-XDR, and XDR P. aeruginosa strains, respectively (log rank, 0.02). Pulsed-field gel electrophoresis showed 10 pairs of non-MDR P. aeruginosa and subsequent MDR-non-XDR strains isolated from the same patients to be clonally identical and another 13 pairs (8 MDR-non-XDR and 5 XDR) to be unrelated. There was one specific clone between the 8 MDR-non-XDR strains and an identical genotype in the 5 XDR isolates. The Cox regression analysis identified MDR P. aeruginosa acquisition as associated with the underlying disease severity (adjusted hazard ratio [aHR], 1.97; 95% confidence interval [CI], 1.22 to 3.18; P = 0.006) and prior use of fluoroquinolones (aHR, 1.02; 95% CI, 1.00 to 1.04; P = 0.039), group 2 carbapenems (aHR, 1.03; 95% CI, 1.00 to 1.07; P = 0.041), and ertapenem (aHR, 1.08; 95% CI, 1.02 to 1.14; P = 0.004). The epidemiology of MDR P. aeruginosa is complex, and different clusters may coexist. Interestingly, ertapenem was found to be associated with the emergence of MDR isolates.

9 October 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OGOriol Gasch
Oriol Gasch
MCM. Camoez
M. Camoez
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
BPB. Padilla
B. Padilla
VPV. Pintado
V. Pintado
NLNieves Larrosa
Nieves Larrosa